A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
Resources and Tools
Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
This month’s Connecting Care episode discusses the impact of structural racism at the intersection of HIV and OUD care and opportunities to think outside of the box to effect change.
For Boston Health Care for the Homeless nurse Megan Sonderegger, providing client-centered care means literally meeting her clients where they are.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
There are so many factors that impact adherence and health outcomes. During this Connecting Care podcast, Drs. Alex Walley, Jessica Taylor, and Sim Kimmel discuss HIV prevention and treatment among people who inject drugs.
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This article describes how the HIV testing window period is a challenge related to prescribing PrEP for people who inject drugs, and discusses current approaches and how data are needed to help guide best practices.
This document contains slides for the September 2020 Models of Integrated Care for HIV and Opioid Use Disorder: Considerations for Community and Clinical Settings webinar.